Newsletter Tool

Today’s Big News

Jul 9, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

uniQure claims latest interim data shows gene therapy can slow Huntington’s disease

Fierce Biotech Fundraising Tracker '24: SciRhom switches on with $68M Series A; Myricx makes $114M Series A push

Cancer drug from lab of bankrupt biotech works against COVID-19 and MRSA lung damage in mice

'Active' vaccine adjuvant boosts COVID-19 and flu antibodies in mice

Featured

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

By Nick Paul Taylor

Mikael Dolsten’s time at Pfizer is coming to an end. After 15 years, including a career-defining pandemic period, the chief scientific officer will leave Pfizer once the drugmaker finds his successor.

uniQure claims latest interim data shows gene therapy can slow Huntington’s disease

By James Waldron

The clinical journey for uniQure’s Huntington’s disease gene therapy got off to a bumpy start, but now the company says the latest interim data shows a slowing of disease progression.

Fierce Biotech Fundraising Tracker '24: SciRhom switches on with $68M Series A; Myricx makes $114M Series A push

By Gabrielle Masson,Annalee Armstrong,Darren Incorvaia,Max Bayer

Welcome to Fierce Biotech's Fundraising Tracker, 2024's version.

Cancer drug from lab of bankrupt biotech works against COVID-19 and MRSA lung damage in mice

By Helen Floersh

Just in time for a summer COVID wave to remind us that SARS-CoV-2 is here to stay, researchers at the University of California San Diego have published new findings that show an experimental cancer drug developed by a now-bankrupt biotech can suppress a key driver of lung inflammation.

'Active' vaccine adjuvant boosts COVID-19 and flu antibodies in mice

By Helen Floersh

Compounds called adjuvants are key to making vaccines created from inactive viruses strong enough to generate an immune response. Now, researchers think they may have found one of the most potent ones so far: an immunomodulating small molecule called PVP-037.

House Speaker Mike Johnson pledges vote for BIOSECURE as China-targeting bill hangs in limbo

By Fraiser Kansteiner

Ahead of an election in November—and amid a period of legislative uncertainty for the China-targeting BIOSECURE Act—U.S. House Speaker Mike Johnson has pledged to hold a vote for the controversial bill before the year is out.

Lilly's Mounjaro triggers more weight loss than Novo Nordisk's Ozempic: study

By Kevin Dunleavy

Is Eli Lilly’s Mounjaro or Novo Nordisk’s Ozempic more effective in helping patients lose weight? While a head-to-head trial pitting the two treatments remains ongoing, new evidence shows that Lilly’s tirzepatide may be the superior weight loss product.

FDA shares draft guidance on tackling misinformation online, offering flexibility to industry

By Nick Paul Taylor

Want to challenge online misinformation about your products? The FDA has set out pointers about how to proceed—and how it will regulate companies’ responses—in draft guidance that is open for comment for 90 days.

Fierce podcasts

Don’t miss an episode

The best biopharma M&A deals

In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.

Designing with neurodiversity in mind

A closer look at 'friend-shoring' and the drug shortage challenge

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences